Last reviewed · How we verify
Budesonide 200 microgram/Puff, HFA MDI
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release.
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide 200 microgram/Puff, HFA MDI |
|---|---|
| Also known as | Duasma 200 mcg inhaler |
| Sponsor | Intech Biopharm Ltd. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Budesonide is a selective glucocorticoid receptor agonist that acts locally in the lungs when delivered via inhaled route. It suppresses the production of inflammatory cytokines, reduces recruitment of inflammatory cells, and decreases mucus production in the airways. This anti-inflammatory action reduces airway hyperresponsiveness and improves airflow obstruction.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Throat irritation
- Hoarseness
- Oral candidiasis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide 200 microgram/Puff, HFA MDI CI brief — competitive landscape report
- Budesonide 200 microgram/Puff, HFA MDI updates RSS · CI watch RSS
- Intech Biopharm Ltd. portfolio CI